Replies to post #389438 on Amarin Corp Plc (AMRN)

[ggwpq]

zip, based on this week's script data from raf:

Vascepa
TRx 64,464; +4.8% (+2,948) w/w; -21.5% y/y
NRx 29,796; +10.2% (+2,752) w/w; -19.7% y/y
Ref 34,668; +0.6% (+196) w/w; -22.9% y/y

Lovaza (Fake & Brand)
TRx 65,492; +9.1% (+5,450) w/w; +1.9% y/y
NRx 32,289; +14.3% (+4,046) w/w; +2.8% y/y
Ref 33,203; +4.4% (+1,404) w/w; +1.0% y/y

Fake Vascepa
TRx 40,043;

L+gV=105535 Vs V=64464

[Whalatane]

Zip. Those EU countries that reimburse …will probably only do so for secondary prevention.

What % of current US sales of Lovaza , GV and V would you ( or anyone reading this ) guess to be secondary prevention ASCVD sales ?

Kiwi

[Tatsumaki]

I don't care about volume of Rx. I care about how much they can actually profit and if that is enough to meaningfully push those 420 million shares they've tallied up higher. If they burn thru their revs funding a heavy sales staff and excessive executive compensation like they did it the US, then just dont bother. They were making $600 Mil a year in the US at one point with 1 or 2 cash flow positive quarters that they ate up with compensation. At that point, the company is just for them and not for shareholders.

They should just sell these markets off to a partner and bank the royalties cause sales and support staff to sell one lousy drug is financially inefficient as hell.